Reslizumab in the management of poorly controlled asthma: the data so far

References

• HumbertMBusseWHananiaNAOmalizumab in asthma: an update on recent developmentsJ Allergy Clin Immunol Pract20142552553625213045
   PubMed Web of Science ®Google Scholar
• CorriganCJKayABT cells and eosinophils in the pathogenesis of asthmaImmunol Today199213125015071361126
   PubMedGoogle Scholar
• WellerPFThe immunobiology of eosinophilsN Engl J Med199132416111011182008184
   PubMed Web of Science ®Google Scholar
• BusseWWLemanskeRFJrAsthmaN Engl J Med2001344535036211172168
   PubMed Web of Science ®Google Scholar
• Peters-GoldenMHendersonWRJrLeukotrienesN Engl J Med2007357181841185417978293
   PubMed Web of Science ®Google Scholar
• JohanssonMWActivation states of blood eosinophils in asthmaClin Exp Allergy201444448249824552191
   PubMed Web of Science ®Google Scholar
• WalkerCCheckelJCammisuliSLeibsonPJGleichGJIL-5 production by NK cells contributes to eosinophil infiltration in a mouse model of allergic inflammationJ Immunol19981614196219699712067
   PubMed Web of Science ®Google Scholar
• NussbaumJCVan DykenSJvon MoltkeJType 2 innate lymphoid cells control eosinophil homeostasisNature2013502747024524824037376
   PubMed Web of Science ®Google Scholar
• HoganMBPiktelDLandrethKSIL-5 production by bone marrow stromal cells: implications for eosinophilia associated with asthmaJ Allergy Clin Immunol2000106232933610932078
   PubMed Web of Science ®Google Scholar
• LampinenMCarlsonMHåkanssonLDVengePCytokine-regulated accumulation of eosinophils in inflammatory diseaseAllergy200459879380515230810
   PubMed Web of Science ®Google Scholar
• SpringerTATraffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigmCell19947623013147507411
   PubMed Web of Science ®Google Scholar
• HynesROIntegrins: bidirectional, allosteric signaling machinesCell2002110667368712297042
   PubMed Web of Science ®Google Scholar
• JohanssonMWKellyEABusseWWJarjourNNMosherDFUp-regulation and activation of eosinophil integrins in blood and airway after segmental lung antigen challengeJ Immunol2008180117622763518490765
   PubMed Web of Science ®Google Scholar
• JohanssonMWGundersonKAKellyEAAnti-IL-5 attenuates activation and surface density of β(2)-integrins on circulating eosinophils after segmental antigen challengeClin Exp Allergy201343329230323414537
   PubMed Web of Science ®Google Scholar
• van RijtLvon RichthofenHvan ReeRType 2 innate lymphoid cells: at the cross-roads in allergic asthmaSemin Immunopathol201638448349626965110
   PubMed Web of Science ®Google Scholar
• Klein WolterinkRGKleinjanAvan NimwegenMPulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthmaEur J Immunol20124251106111622539286
   PubMed Web of Science ®Google Scholar
• EganRWAthwahlDChouCCInhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5Int Arch Allergy Immunol19951071–33213227613159
   PubMed Web of Science ®Google Scholar
• ZhangJKuvelkarRMurgoloNJMapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5Int Immunol199911121935194410590259
   PubMed Web of Science ®Google Scholar
• EganRWAthwahlDChouCCPulmonary biology of anti-interleukin 5 antibodiesMem Inst Oswaldo Cruz199792Suppl 269739698918
   PubMed Web of Science ®Google Scholar
• EganRWAthwalDBodmerMWEffect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivityArzneimittelforschung199949977979010514907
   PubMed Web of Science ®Google Scholar
• KipsJCO’ConnorBJLangleySJEffect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot studyAm J Respir Crit Care Med2003167121655165912649124
   PubMed Web of Science ®Google Scholar
• CastroMMathurSHargreaveFReslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled studyAm J Respir Crit Care Med2011184101125113221852542
   PubMed Web of Science ®Google Scholar
• PinIGibsonPGKolendowiczRUse of induced sputum cell counts to investigate airway inflammation in asthmaThorax199247125291539140
   PubMed Web of Science ®Google Scholar
• PetersSPCounterpoint: is measuring sputum eosinophils useful in the management of severe asthma? No, not for the vast majority of patientsChest2011139612731275 discussion 1275–127821652555
   PubMed Web of Science ®Google Scholar
• RothenbergMEEosinophiliaN Engl J Med199833822159216009603798
   PubMed Web of Science ®Google Scholar
• CastroMZangrilliJWechslerMEReslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trialsLancet Respir Med20153535536625736990
   PubMed Web of Science ®Google Scholar
• CorrenJWeinsteinSJankaLZangrilliJGarinMPhase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil countsChest Epub2016324
   Web of Science ®Google Scholar
• BjermerLLemiereCMasperoJWeissSZangrilliJGerminaroMReslizumab for inadequately controlled asthma with elevated blood eosinophil level: a randomized phase 3 studyChest Epub201644
   Web of Science ®Google Scholar
• KlionADLawMANoelPKimYJHavertyTPNutmanTBSafety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndromeBlood200410382939294115070668
   PubMed Web of Science ®Google Scholar
• HartTKCookRMZia-AmirhosseiniPPreclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeysJ Allergy Clin Immunol2001108225025711496242
   PubMed Web of Science ®Google Scholar
• Menzies-GowAFlood-PagePSehmiRAnti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmaticsJ Allergy Clin Immunol2003111471471912704348
   PubMed Web of Science ®Google Scholar
• LiuYZhangSLiDWJiangSJEfficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trialsPLoS One201383e5987223544105
   PubMed Web of Science ®Google Scholar
• OrtegaHGLiuMCPavordIDMepolizumab treatment in patients with severe eosinophilic asthmaN Engl J Med2014371131198120725199059
   PubMed Web of Science ®Google Scholar
• BelEHWenzelSEThompsonPJOral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthmaN Engl J Med2014371131189119725199060
   PubMed Web of Science ®Google Scholar
• KoikeMNakamuraKFuruyaAEstablishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activityHum Antibodies2009181–2172719478395
   PubMedGoogle Scholar
• KolbeckRKozhichAKoikeMMEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity functionJ Allergy Clin Immunol201012561344135320513525
   PubMed Web of Science ®Google Scholar
• BusseWWKatialRGossageDSafety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthmaJ Allergy Clin Immunol201012561237124420513521
   PubMed Web of Science ®Google Scholar
• CastroMWenzelSEBleeckerERBenralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging studyLancet Respir Med201421187989025306557
   PubMed Web of Science ®Google Scholar
• Teva Branded Pharmaceutical Products, R&D Inc.An efficacy and safety study of reslizumab subcutaneous in patients with oral corticosteroid dependent asthma and elevated blood eosinophils Available from: https://clinicaltrials.gov/ct2/show/NCT02501629?term=NCT02501629&rank=1. NLM identifier: NCT02501629Accessed May 1, 2016
   Google Scholar
• Teva Branded Pharmaceutical Products, R&D Inc.Study of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils Available from: https://clinicaltrials.gov/ct2/show/NCT02452190?term=NCT02452190&rank=1. NLM identifier: NCT02452190Accessed May 1, 2016
   Google Scholar
• GevaertPLang-LoidoltDLacknerANasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polypsJ Allergy Clin Immunol200611851133114117088140
   PubMed Web of Science ®Google Scholar
• GevaertPVan BruaeneNCattaertTMepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposisJ Allergy Clin Immunol2011128598999521958585
   PubMed Web of Science ®Google Scholar
• HumbertMBusseWHananiaNAOmalizumab in asthma: an update on recent developmentsJ Allergy Clin Immunol Pract20142552553625213045
   PubMed Web of Science ®Google Scholar
• CastroMRubinASLavioletteMEffectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trialAm J Respir Crit Care Med2010181211612419815809
   PubMed Web of Science ®Google Scholar